Current Report Filing (8-k)
August 21 2018 - 8:26AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event
reported): August 17, 2018
RXi
PHARMACEUTICALS
CORPORATION
(Exact name of registrant as specified
in its charter)
|
|
|
|
|
Delaware
|
|
001-36304
|
|
45-3215903
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
257 Simarano Drive, Suite 101
Marlborough, Massachusetts 01752
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s telephone number,
including area code: (508) 767-3861
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On August 17, 2018, RXi Pharmaceuticals Corporation (the “Company”)
received written notice (the “Notification Letter”) from the Nasdaq Stock Market notifying the Company that it had
regained compliance with the minimum stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) for continued
listing on The Nasdaq Capital Market. The Notification Letter was sent following the filing of the Company’s Form 10-Q dated
August 14, 2018, evidencing stockholders’ equity of $3,272,000 for the period ended June 30, 2018.
* * *
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
RXi PHARMACEUTICALS CORPORATION
|
|
|
|
|
Date: August 21, 2018
|
|
|
|
By:
|
|
/s/ Geert Cauwenbergh
|
|
|
|
|
|
|
|
|
Geert Cauwenbergh, Dr. Med. Sc.
Chief Executive Officer
|
RXI Pharmaceuticals Corporation (NASDAQ:RXII)
Historical Stock Chart
From Apr 2024 to May 2024
RXI Pharmaceuticals Corporation (NASDAQ:RXII)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Rxi Pharmaceuticals Corp. (MM) (NASDAQ): 0 recent articles
More Rxi Pharmaceuticals Corp News Articles